A Study to Evaluate the Clinical Outcomes of Efgartigimod PH20 SC in Adults With New-onset Generalized Myasthenia Gravis (gMG)

Inclusion Criteria:

• Is at least 18 years when signing the ICF

• Has been diagnosed with gMG of MGFA class II, III, or IV

• Is seropositive for AChR-Ab

• Is treatment-naive for gMG or has been administered AChEI for the treatment of gMG

• Had onset of generalized MG signs and/or symptoms within 12 months before screening;candidates who also had onset of ocular MG signs and/or symptoms within 24 monthsbefore screening may be enrolled in the study

• Has an MG-ADL score ≥5

Exclusion Criteria:

• gMG diagnosis of MGFA class I or V

• Underwent a thymectomy prior to screening, except thymectomy for treatment ofnonmalignant thymoma prior to the gMG diagnosis

• Prior or current use of any of any systemic corticosteroid therapy or nonsteroidalimmunosuppressive therapy for the treatment of gMG